New analysis from NRC Health reveals that integrating real-time patient sentiment tools like Net Promoter Score with traditional HCAHPS surveys can accelerate improvements in care quality and directly impact Medicare reimbursements under value-based programs.
With pharmaceutical companies increasingly deploying AI in direct-to-consumer platforms, the regulatory landscape remains fragmented. In the absence of comprehensive federal action, states are stepping in with disparate laws to address privacy and safety concerns, creating a complex compliance challenge for the industry.
The U.S. Food and Drug Administration has issued a complete response letter for Aquestive Therapeutics' oral film drug designed to treat severe allergic reactions, the company announced Monday, delaying a potential new option for millions at risk.
Medtronic secures a key European regulatory nod for its latest pulsed field ablation catheter while deepening its collaboration with Mindray, signaling a strategic push into high-growth areas of cardiac care and ambulatory surgery.
Swiss healthcare group Galenica has delivered robust returns for long-term shareholders, with a total return of 90% over five years, significantly outpacing the broader market. While recent performance has moderated, the stock's journey highlights the value of consistent earnings growth and dividends.
Egypt reopened the Rafah border crossing on Tuesday, allowing the first medical evacuation from Gaza since its latest closure. A critically wounded Palestinian patient was transferred to an Egyptian hospital, amid ongoing hostilities in the Strip.
Piper Sandler and Barclays have raised price targets for CytomX Therapeutics (CTMX), citing promising early-phase data for its experimental colorectal cancer therapy. Updated results from a larger patient cohort are expected this quarter.
Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.
Apis Capital's flagship fund, which surged 55% in 2025, spotlights clinical-stage biotech Celcuity in its latest investor letter, citing the company's novel platform for matching cancer patients with targeted therapies.
The European CE Mark under the stringent MDR has been granted for Cynosure Lutronic's innovative fractional resurfacing system, designed to improve safety and patient comfort through advanced cooling and precision technology.
Glaukos Corporation secures a significant FDA nod allowing repeated administration of its sustained-release iDose TR implant, broadening treatment options for patients with glaucoma and potentially reshaping long-term care paradigms.
Sanofi's experimental oral drug venglustat demonstrated significant neurological benefits for patients with Type 3 Gaucher disease in a late-stage trial, but failed to meet its primary endpoint in a separate study for Fabry disease, casting uncertainty on its regulatory path.
After nearly two years of near-total closure, the Rafah border crossing between Gaza and Egypt is set to reopen under a coordinated pilot operation. The move, a key element of international ceasefire efforts, will initially allow hundreds of critically ill patients and their families to seek medical care abroad.
ResMed reports robust revenue and margin expansion in its fiscal Q2 2026, driven by strong device and mask sales. Management highlights strategic investments in AI-powered patient tools and views GLP-1 medications as a potential catalyst for future demand.
NewtekOne (NASDAQ: NEWT) reported robust Q4 and full-year 2025 results, highlighting the third anniversary of its OCC-chartered bank. The financial holding company saw net income rise 16.4% to $80 million, driven by strong deposit growth, successful securitizations, and a focus on serving independent business owners with long-term, 'patient capital' loans.
The FDA has issued a complete response letter for Aquestive Therapeutics' sublingual epinephrine film Anaphylm, citing concerns over packaging and user instructions. The company aims to address the issues and resubmit its application by the third quarter of this year.
As major indices climb, investors are sifting through economic crosscurrents to find resilient tech innovators. We examine three companies—Veracyte, monday.com, and Zeta Global—whose strategic moves and financial momentum position them for potential growth.
Despite underperforming the broader market since August 2025, insurance marketplace platform MediaAlpha (MAX) exhibits robust fundamentals—including sustained sales growth, expanding cash flow margins, and rising returns on capital—that could signal significant upside potential for patient investors.
The FDA has cleared Intuitive Surgical's latest robotic system for use in certain heart surgeries, marking a strategic expansion into one of healthcare's largest and most complex service lines and potentially reshaping hospital capital planning for robotics.
Despite a recent 9.4% share price decline, Bytes Technology Group (BYIT) showcases exceptional financial health with a 69% ROE, suggesting the current weakness may be a buying opportunity for patient investors.
